David Steinberg
General Partner at Longwood Fund
Milton, Massachusetts
Overview
Work Experience
Chief Business Officer
2024 - Current
Advancements in AI and drug discovery are creating more candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately limit the number of new medicines that can reach patients, Formation Bio, founded in 2016 as TrialSpark Inc., has built technology platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies, research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to bring new medicines to patients. The company is backed by investors across pharma and tech, including a16z, Sequoia, Sanofi, Thrive Capital, Sam Altman, John Doerr, Spark Capital, SV Angel Growth, and others.
Formation Bio is a drug development company that strives to provide treatments to patients faster by reimagining clinical trials.
Raised $528,000,000.00 from SV Angel, Andreessen Horowitz, Sanofi, FPV Ventures, Thrive Capital, Lachy Groom, Sequoia Capital and Emerson Collective.
Board Member, Founding CEO
2022 - 2024
Carbon Biosciences is a biotech company that engages in the novel parvovirus gene therapy.
Raised $38,000,000.00 from Cystic Fibrosis Foundation, Longwood Fund, Astellas Venture Management, Solasta Ventures, Camford Capital, Agent Capital and UTokyo Innovation Platform.
Chairman, Founding CEO
2021 - 2024
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.
Raised $75,000,000.00 from Longwood Fund, MRL Ventures Fund, 8VC, Omega Funds, MPM Capital, Mass General Brigham Ventures, Eli Lilly & Company Foundation, Heritage Medical Systems, Arkin Bio Ventures and Ono Venture Investment.
Board Member
2021 - 2024
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
Raised $100,000,000.00 from Forbion Capital Partners, Longwood Fund, Omega Funds and Atlas Venture.
Chairman, Founding CEO
2020 - 2024
Be Biopharma (www.be.bio) is a leader in developing B cells as medicines, treating disease with the human body’s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, re-dosable and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, MD, and Richard James, PhD, Be Biopharma is re-imagining medicine based on the power of B cell therapy
Be Biopharma is developing B ceaBe Biopharma is a biotech research company that develops a class of B cells as medicines.lls as medicines.
Raised $264,000,000.00 from Longwood Fund, Bristol-Myers Squibb, Alta Partners, Atlas Venture, RA Capital Management, Takeda Ventures and ARCH Venture Partners.
General Partner
2019 - 2024
Venture Partner
2018 - 2019
Longwood Fund finances science-based companies that develop novel solutions for medical problems.
Board Member
2020 - 2023
Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.
Raised $116,000,000.00 from Catalio Capital Management, Longwood Capital Partners, Longitude Capital, Biotechnology Value Fund, Alta Partners and Frazier Life Sciences.
Founding CEO, former Chairman
2019 - 2021
Pyxis Oncology (NASDAQ:PYXS) is developing therapeutics to promote the body's immune response to cancer, based on new insights into the tumor microenvironment. www.pyxisoncology.com
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Raised $224,000,000.00 from StemPoint Capital, Deep Track Capital, Blue Owl, Ridgeback Capital and Laurion Capital Management.
Co-Founder
2017 - 2020
Targeting the biology of aging to prevent or treat aging-related diseases
Founding CEO
2016 - 2018
Vor Biopharma (NASDAQ:VOR) is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells.